Patent · US Active

Composition comprising KA11 polypeptide or gene encoding the same for inhibiting angiogenesis, and use thereof

US10517925B2 · kind B2 · utility

0Cited by
1References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 4, 2016
Grant dateDec 31, 2019
Priority date
Expiry dateMay 4, 2036

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N33/574
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Provided are a composition including a Kang AI 1 (KAI1) polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.